D: Filing D

Oct 30 01:58

424B5: Prospectus

Oct 21 21:35

8-K: Securities Purchase Agreement

Oct 21 21:35

8-K: bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer

Oct 10 21:25

8-K: bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test

Oct 9 21:21

8-K: Poll Results of 2024 Extraordinary General Meeting

Oct 7 20:03

424B3: Prospectus

Sep 24 04:04

3: Initial statement of beneficial ownership of securities-Officer Edwards James Michael

Sep 21 05:03

EFFECT: Others

Sep 20 18:02

CORRESP: CORRESP

Sep 18 01:07

UPLOAD: Others

Sep 17 01:07

S-1: General form for registration of securities under the Securities Act of 1933

Sep 12 05:36

DEF 14A: Definitive information statements

Sep 6 04:43

PRE 14A: Preliminary proxy statements relating to merger or acquisition

Aug 24 05:22

8-K: Appointment of new Chief Financial Officer

Aug 24 05:17

424B3: Prospectus

Aug 15 04:30

424B3: Prospectus

Aug 15 04:30

10-Q: Q2 2024 Earnings Report

Aug 14 21:39

D: Filing D

Aug 13 04:01

D: Filing D

Aug 13 04:01